The NPM-ALK and the ATIK-ALK fusion genes can be detected in non-neoplastic cells

American Journal of Pathology

Volumn 158, Issue 6, 2001, Pages 2185-2193

  Maes, Brigitte ^a,c   Vanhentenrijk, Vera ^a   Wlodarska, Iwona ^b   Cools, Jan ^b   Peeters, Benjamin ^a   Marynen, Peter ^b   De Wolf Peeters, Christiane ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GENE PRODUCT; PROTEIN ATIC ALK; PROTEIN NPM ALK; UNCLASSIFIED DRUG; ATIC ALK FUSION PROTEIN, HUMAN; ATIC-ALK FUSION PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; P80(NPM ALK) PROTEIN; P80(NPM-ALK) PROTEIN; PROTEIN TYROSINE KINASE; RNA;

ARTICLE; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE ISOLATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CASE REPORT; COMPARATIVE STUDY; GENETICS; HISTIOCYTIC LYMPHOMA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KARYOTYPING; LYMPHOID TISSUE; METABOLISM; SENSITIVITY AND SPECIFICITY;

HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LYMPHOID TISSUE; LYMPHOMA, LARGE-CELL; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC;

EID: 0034743563     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64690-1     Document Type: Article

References (44)

1. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
2. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
3. Anaplastic large cell lymphoma and its morphological variants
4. CD30/Ki-1-positive lymphoproliferative disorders of the skin -Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group
5. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: A clinicopathologic study of 65 cases
6. CD30-positive large cell lymphomas (a "Ki-1 lymphoma") are associated with a chromosomal translocation involving 5q35
7. The t(2;5) or NPM-ALK translocation in lymphomas: Diagnostic considerations
8. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase
9. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monocronal antibody ALK1
10. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum
11. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
12. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
13. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity
14. Nuclyeolar localization of the nucleophosminyanaplastic lymphoma kinase is not required for malignant transformation
15. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma
16. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
17. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
18. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
19. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
20. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
21. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
22. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
23. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma
24. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: Indication of a common pathogenesis?
25. NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: Results from single-cell cDNA analysis
26. Molecular characterization of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease
27. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
28. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining
29. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
30. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals
31. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November
32. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions
33. Successful use of the same slide for consecutive fluorescence in situ hybridization (FISH) experiments
34. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization
35. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas
36. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations
37. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
38. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
39. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
40. Molecular characterization of CD30+ anaplastic large-cell lymphoma: High frequency of c-myc proto-oncogene activation
41. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
42. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
43. Aberrant ALK tyrosine kinase signaling: Different cellular lineages, common oncogenic mechanisms?